ERBB2 and breast carcinoma: However, this approach has largely failed to replicate the success obtained with anti‐HER2 therapies in HER2‐positive breast cancers, with median overall survival for HER2‐positive gastric or gastro‐oesophageal junction adenocarcinoma patients receiving trastuzumab showing only modest survival benefit [10].